Asthma. Mild Persistent Asthma, Status asthmaticus
Conditions
Interventions
Intervention 1: Steps before starting the study: Asthmatic subjects referred with cough and history of recurrence with or without reactive airway hyper responsiveness and without wheezing will be trea
Diagnosis
Treatment - Drugs
Steps before starting the study: Asthmatic subjects referred with cough and history of recurrence with or without reactive airway hyper responsiveness and without wheezing will be treated with one puf
After pretest evaluations, patients will be randomly divided in two groups and will be received cromolyn spray or placebo for 40 days four time daily two puff with spacer. Cromolyn and placebo have si
Sponsors
Mashhad Branch-Islamic Azad University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: cough with an intermittent course and history of airway hyper responsiveness; FEV1(Forced Expiratory volume in 1 second) more than 80% (mild asthma); No beneficial effect of inhaled Corticosteroid anti leukotriene during previous treatment. Exclusion criteria: Moderate or severe asthma; FEV1 (Forced Expiratory volume in 1 second) lees than 80%; Asthma with wheezing; Respiratory infection; Treatment with systemic Corticosteroid; Other Obstructive lung disease; Rhinosinositis; Gastro-esophageal Reflux; Vocal Cord Dysfunction; Reactive airway dysfunction syndrome.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chenge of FENO (Fractional Exhaled Nitric Oxide). Timepoint: Before treatment and 40 days after treatment. Method of measurement: Chemilumine scence instrument, No Breath, Bed font company, England.;Chenge of FEV1 (Forced Expiratory volume in 1 second). Timepoint: Before treatment and 40 days after treatment. Method of measurement: Spirometry super Spiro, Micro medical company, England.;Chenge of Sputum Cytology. Timepoint: Before treatment and 40 days after treatment. Method of measurement: Sputum Cytology for frequency of inflammatory cell (Eosinophil, Neutrophil, Macrophage and Lymphocyte) defined by percentage calculated into 200 cell in each high power field Microscopic in magnification 40x in Sputum. | — |
Secondary
| Measure | Time frame |
|---|---|
| Chenge of IL-8. Timepoint: One year later. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Chenge of INF- GAMMA. Timepoint: One year later. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Chenge of IL-17. Timepoint: One year later. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Chenge of TLR-2. Timepoint: One year later. Method of measurement: Enzyme-linked immunosorbent assay (ELISA). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Mirsadraee
Mashhad Branch-Islamic Azad University
Outcome results
None listed